Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis. Lee KH, Lee S, Park YH, Mun YC, et al. Leukemia 2024;38:451-454.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lee KH, Lee S, Park YH, Mun YC, et al. Interleukin-15 and -21-activated, donor-derived NK cell infusion after haploidentical HCT in high-risk AML and MDS-a cohort analysis. Leukemia 2024;38:451-454.
PMID: 38135760